dx11 Search Results


93
fluidigm 3171013b

3171013b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3171013b/product/fluidigm
Average 93 stars, based on 1 article reviews
3171013b - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Becton Dickinson dnam-1 fitc
NK-activating receptors in PBNK and UCB-NK and their ligand expression in cervical cancer cell lines and their influence on NK cytotoxicity. a Percentage of positive cells within the NK cell population for NK-activating receptors <t>DNAM-1</t> and NKG2D for PBNK only, PBNK stimulated with cytokines (IL-2 + IL-15) and UCB-NK only were determined by flow cytometry. The data presented is from three representative donors for PBNK and UCB-NK. PBNK only are denoted by open circles , PBNK (IL-2 + IL-15) are denoted by closed circles and UCB-NK only by closed squares . b Representative example of histograms showing geometric mean fluorescence intensity (MFI) for NK-activating ligands PVR (ligand of DNAM-1 receptor), MICA/B and ULBP1, −3 and −2/5/6 (ligands of NKG2D receptor). c PBNK and UCB-NK were coated with NKG2D and/or DNAM-1 blocking antibodies and incubated with C33A and SiHa cells. Cytotoxicity levels (Δ7AAD) were measured from 7AAD + C33A and SiHa cells at the end of a 4 h assay. Data presented are means of triplicate values from three different PBNK and three different UCB-NK donors; Bars represent mean ± SEM. * P < 0.05 and ** P < 0.01 calculated with paired, two-way ANOVA multiple comparisons of column means
Dnam 1 Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dnam-1 fitc/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
dnam-1 fitc - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Yamaha Corporation keyboard synthesizers dx11
NK-activating receptors in PBNK and UCB-NK and their ligand expression in cervical cancer cell lines and their influence on NK cytotoxicity. a Percentage of positive cells within the NK cell population for NK-activating receptors <t>DNAM-1</t> and NKG2D for PBNK only, PBNK stimulated with cytokines (IL-2 + IL-15) and UCB-NK only were determined by flow cytometry. The data presented is from three representative donors for PBNK and UCB-NK. PBNK only are denoted by open circles , PBNK (IL-2 + IL-15) are denoted by closed circles and UCB-NK only by closed squares . b Representative example of histograms showing geometric mean fluorescence intensity (MFI) for NK-activating ligands PVR (ligand of DNAM-1 receptor), MICA/B and ULBP1, −3 and −2/5/6 (ligands of NKG2D receptor). c PBNK and UCB-NK were coated with NKG2D and/or DNAM-1 blocking antibodies and incubated with C33A and SiHa cells. Cytotoxicity levels (Δ7AAD) were measured from 7AAD + C33A and SiHa cells at the end of a 4 h assay. Data presented are means of triplicate values from three different PBNK and three different UCB-NK donors; Bars represent mean ± SEM. * P < 0.05 and ** P < 0.01 calculated with paired, two-way ANOVA multiple comparisons of column means
Keyboard Synthesizers Dx11, supplied by Yamaha Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/keyboard synthesizers dx11/product/Yamaha Corporation
Average 90 stars, based on 1 article reviews
keyboard synthesizers dx11 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GeneTex cd226 blocking antibody dx11
(A) BALB/c WT or <t>Cd226</t> −/− mice inoculated with syngeneic CT26 tumor cells and treated with isotype control, anti-PD-1, or anti-TIGIT antibodies. Tumor growth was monitored and grouped analysis and growth curves for each individual animal (n = 10 per group) are shown. Tumor volume remaining below 32 mm 3 was considered to be a complete response (CR). p values are shown for end of study at day 23 using two-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. (B) CD226 deficiency impairs cytotoxicity of CD8 + T cells. WT OT-I cells (black lines) or Cd226 −/− OT-I cells (red lines) were used as effector cells against B16F10 melanoma or PVR/PVRL2-deficient (PVR −/− PVRL2 −/− ) B16F10 target cells pulsed with OVA (SIINFEKL) peptide. Representative real-time profiling of killing is shown on the left panel. Scatterplot (right panel) shows percent cytotoxicity at the 3 h time point. Data are shown as mean ± SD of three independent experiments. p values are shown for one-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.0001.
Cd226 Blocking Antibody Dx11, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd226 blocking antibody dx11/product/GeneTex
Average 90 stars, based on 1 article reviews
cd226 blocking antibody dx11 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Abaqus Inc stress field of dx11
Bearing capacity per unit volume of <t> DX11. </t>
Stress Field Of Dx11, supplied by Abaqus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stress field of dx11/product/Abaqus Inc
Average 90 stars, based on 1 article reviews
stress field of dx11 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ExonHit Therapeutics SA eht dx 11
Bearing capacity per unit volume of <t> DX11. </t>
Eht Dx 11, supplied by ExonHit Therapeutics SA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eht dx 11/product/ExonHit Therapeutics SA
Average 90 stars, based on 1 article reviews
eht dx 11 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier






Image Search Results


Journal: Cell

Article Title: A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

doi: 10.1016/j.cell.2022.01.012

Figure Lengend Snippet:

Article Snippet: CD226 (DX11)-171Yb , Fluidigm , Cat# 3171013B, RRID: AB_2756427.

Techniques: Mass Cytometry, Flow Cytometry, Recombinant, Staining, Selection, Antibody Labeling, Labeling, Isolation, Sample Prep, Luminex, Quantitative Proteomics, Generated, Gene Expression, Clone Assay, Marker, Expressing, Mass Spectrometry, Derivative Assay, RNA Sequencing, Sequencing, Illumina Sequencing, Software, Variant Assay

NK-activating receptors in PBNK and UCB-NK and their ligand expression in cervical cancer cell lines and their influence on NK cytotoxicity. a Percentage of positive cells within the NK cell population for NK-activating receptors DNAM-1 and NKG2D for PBNK only, PBNK stimulated with cytokines (IL-2 + IL-15) and UCB-NK only were determined by flow cytometry. The data presented is from three representative donors for PBNK and UCB-NK. PBNK only are denoted by open circles , PBNK (IL-2 + IL-15) are denoted by closed circles and UCB-NK only by closed squares . b Representative example of histograms showing geometric mean fluorescence intensity (MFI) for NK-activating ligands PVR (ligand of DNAM-1 receptor), MICA/B and ULBP1, −3 and −2/5/6 (ligands of NKG2D receptor). c PBNK and UCB-NK were coated with NKG2D and/or DNAM-1 blocking antibodies and incubated with C33A and SiHa cells. Cytotoxicity levels (Δ7AAD) were measured from 7AAD + C33A and SiHa cells at the end of a 4 h assay. Data presented are means of triplicate values from three different PBNK and three different UCB-NK donors; Bars represent mean ± SEM. * P < 0.05 and ** P < 0.01 calculated with paired, two-way ANOVA multiple comparisons of column means

Journal: Cancer Immunology, Immunotherapy

Article Title: High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

doi: 10.1007/s00262-016-1919-1

Figure Lengend Snippet: NK-activating receptors in PBNK and UCB-NK and their ligand expression in cervical cancer cell lines and their influence on NK cytotoxicity. a Percentage of positive cells within the NK cell population for NK-activating receptors DNAM-1 and NKG2D for PBNK only, PBNK stimulated with cytokines (IL-2 + IL-15) and UCB-NK only were determined by flow cytometry. The data presented is from three representative donors for PBNK and UCB-NK. PBNK only are denoted by open circles , PBNK (IL-2 + IL-15) are denoted by closed circles and UCB-NK only by closed squares . b Representative example of histograms showing geometric mean fluorescence intensity (MFI) for NK-activating ligands PVR (ligand of DNAM-1 receptor), MICA/B and ULBP1, −3 and −2/5/6 (ligands of NKG2D receptor). c PBNK and UCB-NK were coated with NKG2D and/or DNAM-1 blocking antibodies and incubated with C33A and SiHa cells. Cytotoxicity levels (Δ7AAD) were measured from 7AAD + C33A and SiHa cells at the end of a 4 h assay. Data presented are means of triplicate values from three different PBNK and three different UCB-NK donors; Bars represent mean ± SEM. * P < 0.05 and ** P < 0.01 calculated with paired, two-way ANOVA multiple comparisons of column means

Article Snippet: For NK flow cytometry and blocking experiments, NKG2D PE (clone ON72, Beckman Coulter) and DNAM-1 FITC (clone DX11, BD Pharmingen™) were used at 10 µg/mL.

Techniques: Expressing, Flow Cytometry, Fluorescence, Blocking Assay, Incubation

(A) BALB/c WT or Cd226 −/− mice inoculated with syngeneic CT26 tumor cells and treated with isotype control, anti-PD-1, or anti-TIGIT antibodies. Tumor growth was monitored and grouped analysis and growth curves for each individual animal (n = 10 per group) are shown. Tumor volume remaining below 32 mm 3 was considered to be a complete response (CR). p values are shown for end of study at day 23 using two-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. (B) CD226 deficiency impairs cytotoxicity of CD8 + T cells. WT OT-I cells (black lines) or Cd226 −/− OT-I cells (red lines) were used as effector cells against B16F10 melanoma or PVR/PVRL2-deficient (PVR −/− PVRL2 −/− ) B16F10 target cells pulsed with OVA (SIINFEKL) peptide. Representative real-time profiling of killing is shown on the left panel. Scatterplot (right panel) shows percent cytotoxicity at the 3 h time point. Data are shown as mean ± SD of three independent experiments. p values are shown for one-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.0001.

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet: (A) BALB/c WT or Cd226 −/− mice inoculated with syngeneic CT26 tumor cells and treated with isotype control, anti-PD-1, or anti-TIGIT antibodies. Tumor growth was monitored and grouped analysis and growth curves for each individual animal (n = 10 per group) are shown. Tumor volume remaining below 32 mm 3 was considered to be a complete response (CR). p values are shown for end of study at day 23 using two-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. (B) CD226 deficiency impairs cytotoxicity of CD8 + T cells. WT OT-I cells (black lines) or Cd226 −/− OT-I cells (red lines) were used as effector cells against B16F10 melanoma or PVR/PVRL2-deficient (PVR −/− PVRL2 −/− ) B16F10 target cells pulsed with OVA (SIINFEKL) peptide. Representative real-time profiling of killing is shown on the left panel. Scatterplot (right panel) shows percent cytotoxicity at the 3 h time point. Data are shown as mean ± SD of three independent experiments. p values are shown for one-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.0001.

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Control

(A) Relative gene expression of CD226, CD28, PDCD1, or TIGIT in three different atezolizumab clinical trials (BIRCH, OAK, or POPLAR) in NSCLC. (B) Co-expression of CD226 (left) or CD28 (right) with PDCD1 or TIGIT are positively correlated. Shown is the Spearman correlation coefficient. (C–F) Survival based on CD226 (C), CD28 (D), PDCD1 (E), or TIGIT (F) gene expression. Kaplan-Meier plots of overall survival (OS) are shown for the atezolizumab arm in the indicated clinical trial (BIRCH, OAK, or POPLAR), with patients separated on the basis of gene expression. Patients were dichotimized into top 50% (high, green line) or bottom 50% (low, red line) relative to the median expression over all patients in the corresponding clinical trial. Two-sided p values and hazard ratios from a Cox proportional hazards model are indicated for each plot.

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet: (A) Relative gene expression of CD226, CD28, PDCD1, or TIGIT in three different atezolizumab clinical trials (BIRCH, OAK, or POPLAR) in NSCLC. (B) Co-expression of CD226 (left) or CD28 (right) with PDCD1 or TIGIT are positively correlated. Shown is the Spearman correlation coefficient. (C–F) Survival based on CD226 (C), CD28 (D), PDCD1 (E), or TIGIT (F) gene expression. Kaplan-Meier plots of overall survival (OS) are shown for the atezolizumab arm in the indicated clinical trial (BIRCH, OAK, or POPLAR), with patients separated on the basis of gene expression. Patients were dichotimized into top 50% (high, green line) or bottom 50% (low, red line) relative to the median expression over all patients in the corresponding clinical trial. Two-sided p values and hazard ratios from a Cox proportional hazards model are indicated for each plot.

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Gene Expression, Clinical Proteomics, Expressing

(A) CD45 + cells from NSCLC patient tumors (n = 6) were analyzed by CyTOF. 8,000 downloaded cells per sample were aggregated and clusters generated in an unsupervised manner by uniform approximation and projection (UMAP). Immune cell populations were defined by manual gating and projected onto the UMAP (left). Expression of CD226 (middle) or CD28 (right) across total CD45 + cells was overlaid onto the UMAP. (B) Frequencies of CD8 + T cell expressing CD226 and/or CD28 in NSCLC tumors. CD8 + T cells were subtyped by CD28 + CD226 + (gray), CD28 + CD226 − (blue), CD28 − CD226 + (red), or CD28 − CD226 − (yellow). (C–F) Comparison of expression by frequency (left), and where shown, median ion intensity (right) for indicated markers within CD8 + T cells gated on CD226 and/or CD28 expression. (C) Proliferation marker Ki67. (D) CD27. (E) Checkpoint inhibitors PD-1, TIGIT, and TIM-3. (F) Trm cell marker CD103. Whiskers denote mean ± SD (n = 6). p values are shown for one-way ANOVA with post hoc Tukey’s for multiple comparisons; *p < 0.05, **p < 0.01, ***p < 0.001.

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet: (A) CD45 + cells from NSCLC patient tumors (n = 6) were analyzed by CyTOF. 8,000 downloaded cells per sample were aggregated and clusters generated in an unsupervised manner by uniform approximation and projection (UMAP). Immune cell populations were defined by manual gating and projected onto the UMAP (left). Expression of CD226 (middle) or CD28 (right) across total CD45 + cells was overlaid onto the UMAP. (B) Frequencies of CD8 + T cell expressing CD226 and/or CD28 in NSCLC tumors. CD8 + T cells were subtyped by CD28 + CD226 + (gray), CD28 + CD226 − (blue), CD28 − CD226 + (red), or CD28 − CD226 − (yellow). (C–F) Comparison of expression by frequency (left), and where shown, median ion intensity (right) for indicated markers within CD8 + T cells gated on CD226 and/or CD28 expression. (C) Proliferation marker Ki67. (D) CD27. (E) Checkpoint inhibitors PD-1, TIGIT, and TIM-3. (F) Trm cell marker CD103. Whiskers denote mean ± SD (n = 6). p values are shown for one-way ANOVA with post hoc Tukey’s for multiple comparisons; *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Generated, Expressing, Comparison, Marker

(A) Cluster analysis was performed on scRNA-seq data of CD8 + T cells obtained from all six NSCLC patients and plotted by UMAP dimensionality reduction. Cluster assignments were generated by unsupervised clustering and colored by cluster assignment. Approximate regions of the clusters are demarcated with labeled ovals (top left). (B) Relative expression of T cell-associated genes across CD8 + clusters. (C–E) Individual CD8 + T cells are plotted within each UMAP (left) or plotted by bar graph to depict frequency (right) of CD226 (C), CD28 (D), or CD226 and CD28 (E) expression within each CD8 + T cell cluster.

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet: (A) Cluster analysis was performed on scRNA-seq data of CD8 + T cells obtained from all six NSCLC patients and plotted by UMAP dimensionality reduction. Cluster assignments were generated by unsupervised clustering and colored by cluster assignment. Approximate regions of the clusters are demarcated with labeled ovals (top left). (B) Relative expression of T cell-associated genes across CD8 + clusters. (C–E) Individual CD8 + T cells are plotted within each UMAP (left) or plotted by bar graph to depict frequency (right) of CD226 (C), CD28 (D), or CD226 and CD28 (E) expression within each CD8 + T cell cluster.

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Generated, Labeling, Expressing

(A–E) Representative phospho-tyrosine immunoblots showing CD226 phosphorylation upon co-culture of Jurkat cells expressing indicated receptors with SEE-loaded Raji cells expressing indicated ligands. In (B) and (C), Jurkat cells were pretreated with anti-TIGIT (10A7), anti-PD-1 (pembrolizumab), anti-CD226 (DX11), or in combination. CD226-GFP was enriched by GFP IP after lysing the Raji:Jurkat conjugates at the indicated time points. The “% of max” values under each blot denote the optical densities (OD) of the corresponding bands above normalized to the OD of the strongest band of the same blot. (F) Cartoon on top depicts a liposome-based FRET assay for measuring the recruitment of SC505-labeled SH2 proteins to liposome-reconstituted, Fyn-phosphorylated TIGIT ICD or PD-1 ICD . Shown on the bottom are representative time courses of SC505 FI before and after addition of 1 mM ATP for TIGIT ICD (left) or PD-1 ICD (right). Green stars denote SC505 dye, red stars denote rhodamine-PE lipid, black circles denote His 10 tags.

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet: (A–E) Representative phospho-tyrosine immunoblots showing CD226 phosphorylation upon co-culture of Jurkat cells expressing indicated receptors with SEE-loaded Raji cells expressing indicated ligands. In (B) and (C), Jurkat cells were pretreated with anti-TIGIT (10A7), anti-PD-1 (pembrolizumab), anti-CD226 (DX11), or in combination. CD226-GFP was enriched by GFP IP after lysing the Raji:Jurkat conjugates at the indicated time points. The “% of max” values under each blot denote the optical densities (OD) of the corresponding bands above normalized to the OD of the strongest band of the same blot. (F) Cartoon on top depicts a liposome-based FRET assay for measuring the recruitment of SC505-labeled SH2 proteins to liposome-reconstituted, Fyn-phosphorylated TIGIT ICD or PD-1 ICD . Shown on the bottom are representative time courses of SC505 FI before and after addition of 1 mM ATP for TIGIT ICD (left) or PD-1 ICD (right). Green stars denote SC505 dye, red stars denote rhodamine-PE lipid, black circles denote His 10 tags.

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Western Blot, Phospho-proteomics, Co-Culture Assay, Expressing, Labeling

(A and B) Representative immunoblots showing the degrees of CD226 and TIGIT phosphorylation (pY) after co-culturing Jurkat cells expressing indicated receptors and SEE-loaded Raji cells expressing indicated ligands. Times denote the duration of co-culture before lysis. CD226-GFP and TIGIT-mCherry were captured using GFP IP and mCherry IP, respectively. The “% of max” values under each blot denote the OD of the corresponding bands above normalized to the OD of the strongest band of the same blot. (C) Confocal images of Jurkat:Raji cell conjugates probing the effects of TIGIT on PVR-mediated CD226 accumulation to the Raji:Jurkat interface. Left: depiction of the relevant proteins at the cell conjugate. Middle: confocal and differential interference contrast (DIC) images of a Raji:Jurkat conjugate acquired five minutes after contact. Right: scatterplot summarizing CD226 enrichment indices of the five conditions (means ± SD, n = 20 conjugates from three independent experiments). Scale bars, 5 μm. ****p < 0.0001; ns, not significant; Student’s t test (n = 20). (D and E) Interaction studies between CD226 and TIGIT using FRET. (D) Cell surface TR-FRET signal between acceptor labeled full-length or chimeric Flag-ST-CD226 and donor labeled full length HA-TIGIT. (E) Cell surface expression of Flag-ST-CD226 constructs (black bar) and HA-TIGIT (white bar) as measured by ELISA. Data are average of 2 independent experiments, each performed in triplicate, and shown as mean ± SEM ns = not significant.

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet: (A and B) Representative immunoblots showing the degrees of CD226 and TIGIT phosphorylation (pY) after co-culturing Jurkat cells expressing indicated receptors and SEE-loaded Raji cells expressing indicated ligands. Times denote the duration of co-culture before lysis. CD226-GFP and TIGIT-mCherry were captured using GFP IP and mCherry IP, respectively. The “% of max” values under each blot denote the OD of the corresponding bands above normalized to the OD of the strongest band of the same blot. (C) Confocal images of Jurkat:Raji cell conjugates probing the effects of TIGIT on PVR-mediated CD226 accumulation to the Raji:Jurkat interface. Left: depiction of the relevant proteins at the cell conjugate. Middle: confocal and differential interference contrast (DIC) images of a Raji:Jurkat conjugate acquired five minutes after contact. Right: scatterplot summarizing CD226 enrichment indices of the five conditions (means ± SD, n = 20 conjugates from three independent experiments). Scale bars, 5 μm. ****p < 0.0001; ns, not significant; Student’s t test (n = 20). (D and E) Interaction studies between CD226 and TIGIT using FRET. (D) Cell surface TR-FRET signal between acceptor labeled full-length or chimeric Flag-ST-CD226 and donor labeled full length HA-TIGIT. (E) Cell surface expression of Flag-ST-CD226 constructs (black bar) and HA-TIGIT (white bar) as measured by ELISA. Data are average of 2 independent experiments, each performed in triplicate, and shown as mean ± SEM ns = not significant.

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Western Blot, Phospho-proteomics, Expressing, Co-Culture Assay, Lysis, Labeling, Construct, Enzyme-linked Immunosorbent Assay

Journal: Immunity

Article Title: Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 + T cell responses

doi: 10.1016/j.immuni.2022.02.005

Figure Lengend Snippet:

Article Snippet: CD226 blocking antibody (DX11) , GeneTex , Cat# GTX76029; RRID:AB_377177.

Techniques: Blocking Assay, Recombinant, Software, Sequencing

Bearing capacity per unit volume of  DX11.

Journal: Scientific Reports

Article Title: Multi-objective design and optimization of squeezed branch pile based on orthogonal test

doi: 10.1038/s41598-023-49936-y

Figure Lengend Snippet: Bearing capacity per unit volume of DX11.

Article Snippet: Figure 22 Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Techniques:

Uplift load displacement data.

Journal: Scientific Reports

Article Title: Multi-objective design and optimization of squeezed branch pile based on orthogonal test

doi: 10.1038/s41598-023-49936-y

Figure Lengend Snippet: Uplift load displacement data.

Article Snippet: Figure 22 Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Techniques:

Axial force transfer curve of DX11.

Journal: Scientific Reports

Article Title: Multi-objective design and optimization of squeezed branch pile based on orthogonal test

doi: 10.1038/s41598-023-49936-y

Figure Lengend Snippet: Axial force transfer curve of DX11.

Article Snippet: Figure 22 Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Techniques:

Load sharing curve of DX11.

Journal: Scientific Reports

Article Title: Multi-objective design and optimization of squeezed branch pile based on orthogonal test

doi: 10.1038/s41598-023-49936-y

Figure Lengend Snippet: Load sharing curve of DX11.

Article Snippet: Figure 22 Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Techniques:

Variation of displacement field of DX11 during 1000N loading (Abaqus v6.3).

Journal: Scientific Reports

Article Title: Multi-objective design and optimization of squeezed branch pile based on orthogonal test

doi: 10.1038/s41598-023-49936-y

Figure Lengend Snippet: Variation of displacement field of DX11 during 1000N loading (Abaqus v6.3).

Article Snippet: Figure 22 Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Techniques:

Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Journal: Scientific Reports

Article Title: Multi-objective design and optimization of squeezed branch pile based on orthogonal test

doi: 10.1038/s41598-023-49936-y

Figure Lengend Snippet: Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Article Snippet: Figure 22 Variation of stress field of DX11 during 1000N loading (Abaqus v6.3).

Techniques: